Alzheimer disease cannot be treated with Cognex
Shafazand, M.
Lakartidningen 93(15): 1406
1996
ISSN/ISBN: 0023-7205 PMID: 8667714 Document Number: 455952
Document emailed within 1 workday
Related Documents
Gillen, T.E.; Gregg, K.M.; Yuan, H.; Kurth, M.C.; Krishnan, K.R. 2001: Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease Psychopharmacology Bulletin 35(2): 83-96Mackell, J.A.; Ferris, S.H.; Mohs, R.; Schneider, L.; Galasko, D.; Whitehouse, P.; Schmitt, F.; Sano, M.; Thal, L.J. 1997: Multicenter evaluation of new instruments for Alzheimer's disease clinical trials: summary of results. The Alzheimer's Disease Cooperative Study Alzheimer Disease and Associated Disorders 11 Suppl. 2: S65-S69
Morris, J.C.; Edland, S.; Clark, C.; Galasko, D.; Koss, E.; Mohs, R.; van Belle, G.; Fillenbaum, G.; Heyman, A. 1993: The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease Neurology 43(12): 2457-2465
Fukatsu, R.; Tsuzuki, K.; Hayashi, Y.; Takamaru, Y.; Sasaki, N.; Yoshida, T.; Hatakeyama, Y.; Fuji, N.; Takahata, N. 1997: Recent advances in Alzheimer's disease research--amyloid precursor protein trafficking, processing, and mutations in Alzheimer's disease linked genes Hokkaido Journal of Medical Science 72(1): 3-11
Morris, J.C.; Mohs, R.C.; Rogers, H.; Fillenbaum, G.; Heyman, A. 1988: Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease Psychopharmacology Bulletin 24(4): 641-652
Creţu, O.; Szalontay, A.S.; Chiriţă, R.; Chiriţă, V. 2008: Effect of memantine treatment on patients with moderate-to-severe Alzheimer's disease treated with donepezil Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 112(3): 641-645
Miyakawa, T. 1988: Brain pathology in Alzheimer's disease. Ultrastructure of amyloid fibrils in Alzheimer's disease and Down's syndrome Nihon Rinsho. Japanese Journal of Clinical Medicine 46(7): 1471-1474
Szpak, G.M.; Lechowicz, W.; Lewandowska, E.; Bertrand, E.; Wierzba-Bobrowicz, T.; Gwiazda, E.; Schmidt-Sidor, B.; Dymecki, J. 2001: Neurones and microglia in central nervous system immune response to degenerative processes. Part 1: Alzheimer's disease and Lewy body variant of Alzheimer's disease. Quantitative study Folia Neuropathologica 39(3): 181-192
Bufill, E.; Blesa, R. 2006: Alzheimer's disease and brain evolution: is Alzheimer's disease an example of antagonistic pleiotropy? Revista de Neurologia 42(1): 25-33
Fărcăşel, L. 1988: Current data on the anatomy and physiopathology of Alzheimer's disease (Alzheimer-type senile dementia--ATSD) Revista Medico-Chirurgicala A Societatii de Medici Si Naturalisti Din Iasi 92(2): 289-292
Ng, H.K. 1994: Alzheimer's disease and Alzheimer-type of cerebral degenerations in Chinese Clinical and Experimental Neurology 31: 85-98
Narindrasorasak, S.; Altman, R.A.; Gonzalez-DeWhitt, P.; Greenberg, B.D.; Kisilevsky, R. 1995: An interaction between basement membrane and Alzheimer amyloid precursor proteins suggests a role in the pathogenesis of Alzheimer's disease Laboratory Investigation; A Journal of Technical Methods and Pathology 72(3): 272-282
DE Felice, F.G.; Houzel, J-Christophe.; Garcia-Abreu, Jé.; Louzada, P.Roberto.F.; Afonso, R.C.; Meirelles, M.Nazareth.L.; Lent, R.; Neto, V.Moura.; Ferreira, Sérgio.T. 2001: Inhibition of Alzheimer's disease β-amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: implications for Alzheimer's therapy FASEB Journal 15(7): 1297-1299
Patterson, M.B.; Mack, J.L.; Mackell, J.A.; Thomas, R.; Tariot, P.; Weiner, M.; Whitehouse, P.J. 1997: A longitudinal study of behavioral pathology across five levels of dementia severity in Alzheimer's disease: the CERAD Behavior Rating Scale for Dementia. the Alzheimer's Disease Cooperative Study Alzheimer Disease and Associated Disorders 11(Suppl 2): S40-S44
Brice, A.; Dubois, B.; Agid, Y.; Campion, D.; Martinez, M.; Clerger-Darpoux, F.; Bellis, M.; Mallet, J.; Frebourg, T.; Hannequin, D.; Puel, M.; Ledoze, F.; Pasquier, F.; Zimmerman, M.A.; Thomas-Anterion, C.; Moreaud, O.; Goas, J.Y. 1996: Genetics of dominant autosomal forms of Alzheimer disease: 3 genes and one phenotype. Groupe de Recherche Francais sur la Maladie d'Alzheimer Revue Neurologique (Paris) 152(12): 725-726
Ball, M.J.; Kaye, J.A.; Steiner, I. 1997: Neocortical temporal lobe sclerosis masquerading as Alzheimer dementia: does herpes virus encephalopathy protect against Alzheimer's disease? Clinical Neuropathology 16(1): 1-12
Lara, H.Herman.; Alanís-Garza, E.Javier.; Estrada Puente, Mía.Fernanda.; Mureyko, Lía.Liliana.; Alarcón Torres, D.Alejandro.; Ixtepan Turrent, L. 2015: Nutritional approaches to modulate oxidative stress that induce Alzheimer's disease. Nutritional approaches to prevent Alzheimer's disease Gaceta Medica de Mexico 151(2): 245-251
Scheen, A.J. 1996: Pharma-clinics. Drug of the month. Tacrine (Cognex) Revue Medicale de Liege 51(5): 379-381
Patel, K.R. 2015: Biogen's aducanumab raises hope that Alzheimer's can be treated at its source Managed Care 24(6): 19
Mastaglia, F.L.; Masters, C.L.; Beyreuther, K.; Kakulas, B.A. 1989: Deposition of Alzheimer's disease amyloid (A4) protein in the cerebral cortex in Parkinson's disease Progress in Clinical and Biological Research 317: 475-484